Catalog No.S1878 Synonyms: RS-21592, BW-759
Molecular Weight(MW): 255.23
Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Purity & Quality Control
Choose Selective Antifection Inhibitors
|Description||Ganciclovir is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.|
Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: (1) a deoxyguanosine kinase induced by CMV-infected cells; (2) guanylate kinase; and (3) phosphoglycerate kinase.  Ganciclovir is sufficient to induce cell death in most bystander cells cocultured with HSV-tk-expressing cells.  Ganciclovir significantly reduces DNA synthesis in the transformed cells, whereas Ganciclovir has little effect on DNA synthesis in the nontransformed cells. Ganciclovir exhibits a concentration-dependent reduction in the rate of elongation into mature DNA.  Ganciclovir induces cell cycle arrests rather than direct chemical effect on HSVtk-transduced B16F10 melanoma cells.  Ganciclovir produces only weak inhibition of DNA synthesis. Ganciclovir-treated cells accumulate in early S-phase and remained there until cell death, suggesting that ganciclovir incorporation in the DNA template is important for cytotoxicity.  Ganciclovir-induced apoptosis is due to incorporation of the drug into DNA resulting in replication-dependent formation of DNA double-strand breaks and, at later stages, S and G2/M arrest. Ganciclovir-provoked DNA instability is likely to be responsible for the observed initial decline in Bcl-2 level and caspase-9/-3 activation. 
|In vivo||Antiviral drug ganciclovir (GCV) inhibits the proliferation of microglia in experimental autoimmune encephalomyelitis (EAE). GCV attenuates neuroinflammation and does not significantly restrain the peripheral immune response.|
-  Matthews T, et al. Rev Infect Dis, 1988, 10, S490-494.
-  Hamel W, et al. Cancer Res, 1996, 56(12), 2697-2702.
-  St Clair MH, et al. Antimicrob Agents Chemother, 1987, 31(6), 844-849.
|In vitro||DMSO||27 mg/mL warmed (105.78 mM)|
|In vivo||Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00034385||Completed||Kidney Trasplant||National Institutes of Health Clinical Center (CC)||April 24, 2002||Phase 4|
|NCT00001328||Completed||Brain Neoplasm|Neoplasm Metastasis||National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)||August 21, 1992||Phase 1|
|NCT02927067||Not yet recruiting||Cytomegalovirus (CMV)||Shire||March 2017||Phase 3|
|NCT03004261||Recruiting||Cytomegalovirus Infections|Hematological Disease||Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||November 2016||Phase 4|
|NCT02606266||Not yet recruiting||Congenital Cytomegalovirus (CMV)||Assistance Publique - Hôpitaux de Paris||October 2016||Phase 2|Phase 3|
|NCT02871401||Not yet recruiting||Idiopathic Pulmonary Fibrosis||Vanderbilt University|Genentech, Inc.||September 2016||Phase 1|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.